Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil

Oncology

Volumn 70, Issue 5, 2007, Pages 366-377

  Ciaparrone, M ^a   Quirino, M ^a   Schinzari, G ^a   Zannoni, G ^a   Corsi, D C ^a   Vecchio, F M ^a   Cassano, A ^a   La Torre, G ^a   Barone, C ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

5 fluorouracil; Colorectal cancer; Dihydropyrimidine dehydrogenase; Immunohistochemistry; Thymidine phosphorylase; Thymidylate synthase

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER TISSUE; COLORECTAL CANCER; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 33846085042     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000098110     Document Type: Article

References (54)

1. American Society of Clinical Oncology: Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996;10:2843-2877.
2. Danenberg PV: Thymidylate synthetase: a target enzyme in cancer chemotherapy. Biochim Biophys Acta 1977;473:73-92.
3. van Triest B, Pinedo HM, Giaccone G, Peters GJ: Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Ann Oncol 2000;11:385-391.
4. Kornmann M, Link KH, Lenz HJ, Pillasch J, Metzger R, Butzer U, Leder GH, Weindel M, Safi F, Danenberg KD, Beger HG, Danenberg PV: Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. Cancer Lett 1997;118:29-35.
5. Edler D, Hallstrom M, Johnston PG, Magnusson I, Ragnhammar P, Blomgren H: Thymidylate synthase expression: an independent prognostic marker for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. Clin Cancer Res 2000;6:1378-1384.
6. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, Chabner BA, Allegra CJ: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994;12:2640-2647.
7. Lu ZH, Zhang R, Diasio R: Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J Biol Chem 1992;267:17102-17109.
8. Beck A, Etienne MC, Cheradame S, Fishel JL, Formento P, Renee N, Milano G: A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to fluorouracil. Eur J Cancer 1994;30A:1517-1522.
9. Etienne MC, Cheradame S, Fishel JL, Formento P , Dassonville O, Renee N, Schneider M, Thyss A, Demard F, Milano G: Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995;13:1663-1670.
10. Friedkin D, Roberts D: The enzymatic synthesis of nucleosides. J Biol Chem 1954;207:245-256.
11. Furukawa T, Yoshimura A, Sumizawa T, Haraguchi M, Akiyama SI: Angiogenic factor (letter). Nature 1992;356:668.
12. Miyazono K, Okabe T, Urabe A, Takaku F, Heldin CH: Purification and properties of an endothelial cell growth factor from human platelets. J Biol Chem 1987;262:4098-4103.
13. Moghaddam A, Zhang HT, Fan TP, Hu DE, Lees V, Turley H, Fox SB, Gatter KC, Harris AL, Bicknell R: Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 1995;92:988-1002.
14. Takebayashi Y, Akyiama S, Akiba S, Yamada K, Miyadera K, Sumizawa T, Yamada Y, Murata F, Aikou T: Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 1996;88:1110-1117.
15. Takebayashi Y, Myadera K, Akyama S, Hokita S, Yamada K, Akiba S, Yamada Y, Sumizawa T, Aikou T: Expression of thymidine phosphorylase in human gastric carcinoma. Jpn J Cancer Res 1996;87:288-295.
16. Toi M, Hoshina S, Taniguchi T, Yamamoto Y, Ishitsuka H, Tominaga T: Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer. Int J Cancer 1995;64:79-82.
17. Folkman J: What is the role of thymidine phosphorylase in tumor angiogenesis? J Natl Cancer Inst 1996;88:1091-1092.
18. Schwartz EL, Baptiste N, Wadler S, Makower D: Thymidine phosphorylase mediates the sensitivity of colon carcinoma cells to 5-fluorouracil. J Biol Chem 1995;270:19073-19077.
19. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV: Colorectal cancers responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase and thymidine phosphorylase. Clin Cancer Res 2000;6:1322-1327.
20. Allegra C: Thymidylate synthase levels: prognostic, predictive or both? J Clin Oncol 2002;7:1711-1713.
21. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995;55:1407-1412.
22. Podschun B, Wahler G, Schnackerz KD: Purification and characterization of dihydropyrimidine dehydrogenase from pig liver. Eur J Biochem 1989;185:219-224.
23. Bisgaard K, Pluzek KP: Use of polymer conjugates in immunohistochemistry: a comparative study of a traditional staining method to a staining method utilizing polymer conjugates. Abstracts 21st Int Congr Int Acad Pathol and 12th World Congr Acad Environ Pathol, Budapest, October 20-25, 1996.
24. Kono T, Nishida M, Inagaki N, Tanaka Y, Yoneda M, Kasai S: Development and characterization of 1C6-203, a new monoclonal antibody specific to human thymidine phosphorylase. J Histochem Cytochem 2001;49:131-138.
25. Edler D, Blomgren H, Allegra CJ, Johnston PG, Lagerstedt U, Magnusson I, Ragnhammar P: Immunohistochemical determination of thymidylate synthase in colorectal cancer: methodological studies. Eur J Cancer 1997;33:2278-2281.
26. Oi K, Makino M, Ozaki M, Takemoto H, Yamane N, Nakamura S, Ikeguchi M, Kaibara N: Immunohistochemical dihydropyrimidine dehydrogenase expression is a good prognostic indicator for patients with Dukes' C colorectal cancer. Anticancer Res 2004;24:273-280.
27. Takenoue T, Kitayama J, Takei Y, Umetani N, Matsuda K, Nita ME, Hatano K, Tsuruo T, Nagawa H: Characterization of dihydropyrimidine dehydrogenase on immunohistochemistry in colon carcinoma, and correlation between immunohistochemical score and protein level or messenger RNA expression. Ann Oncol 2000;11:273-279.
28. Kaplan EL, Meier P: Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457-481.
29. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-748.
30. Cox DR: Regression models and life-tables. J R Stat Soc 1972;34:187-220.
31. Diasio RB, Johnson MR: Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res 2000;6:1378-1384.
32. Metzger R, Danenberg K, Leichman CG, Salonga D, Schwartz EL, Wadler S, Lenz HJ, Groshen S, Leichman L, Danenberg PV: High basal expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 1998;4:2371-2376.
33. Popat S, Matakidou A, Houlston RS: Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004;22:529-536.
34. Edler D, Glimelius B, Hallstrom M, Jakobsen A, Johnston PG, Magnusson I, Ragnhammar P, Blomgren H: Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 2001;24:597-602.
35. Sakamoto J, Fukushima M, Hamashima H, Suzuki H, Ito K, Mai M, Saji S, Baba S, Matsushita Y, Nakazato H: Thymidylate synthase expression predicts prognosis of curatively resected colorectal carcinoma patients registered in an adjuvant immunochemotherapy clinical trial (abstract 1031). Proc ASCO 1999;18:268.
36. Iacopetta B, Grieu F, Joseph D, Elsaleh H: A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 2001;85:827-830.
37. Cascinu S, Graziano F, Valentini M, Catalano V, Giordani P, Staccioli MP, Rossi C, Baldelli AM, Grianti C, Muretto P, Catalano G:Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy. Ann Oncol 2001;12:239-244.
38. Allegra JC, Parr LA, Lester EW, Mahoney RM, Sargent DJ, Johnston P, Klein P, Behan K, O'Connel MJ, Levitt R, Kugler JW, Tirona MT, Goldberg RM: Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 2002;20:1735-1743.
39. Allegra CJ, Paik S, Colangelo LH, Parr LA, Kirsch I, Kim G, Klein P, Johnston PG, Wolmark N, Wieand S: Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 2003;21:241-250.
40. Paradiso A, Simone G, Petroni S, Leone B, Vallejo C, Lacava J, Romero A, Machiavelli M, De Lena M, Allegra CJ, Johnston PG: Thymidylate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 2000;82:560-567.
41. Bathe OF, Franceschi D, Livingstone AS, Moffat FL, Tian E, Ardalan B: Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: implications for chemotherapeutic options and survival. Cancer J Sci Am 1999;5:34-40.
42. Corsi DC, Ciaparrone M, Zannoni G, Mancini M, Cassano A, Specchia M, Pozzo C, Martini M, Barone C: Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer. Eur J Cancer 2002;38:527-534.
43. Geoffroy FJ, Allegra CJ, Sinha B, Grem JL: Enhanced cytotoxicity with interleukin-1α and 5-fluorouracil in HCT116 colon cancer cells. Oncol Res 1994;6:581-591.
44. Pritchard DM, Watson AJ, Potten CS, Jackman AL, Hickman JA: Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. Proc Natl Acad Sci USA 1997;94:1795-1799.
45. Nishimura G, Terada I, Kobayashi T, Ninomiya I, Kitagawa H, Fushida S, Fujimura T, Kayahara M, Shimizu K, Ohta T, Miwa K: Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncol Rep 2002;9:479-482.
46. Kornmann M, Schwabe W, Sander S, Kron M, Strater J, Polat S, Kettner E, Weiser HF, Baumann W, Schramm H, Hausler P, Ott K, Behnke D, Staib L, Beger HG, Link KH: Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 2003;9:4116-4124.
47. Kato Y, Matsukawa S, Muraoka R, Tanigawa N: Enhancement of drug sensitivity and a bystander effect in PC-9 cells transfected with a platelet-derived endothelial cell growth factor thymidine phosphorylase cDNA. Br J Cancer 1997;75:506-511.
48. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenetic switch during tumorigenesis. Cell 1996;86:353-364.
49. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 1996;379:88-91.
50. Tahara M, Ochiai M, Fujimoto J, Boku N, Yasui W, Ohtsu A, Tahara E, Yoshida S: Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and BCL-2, and clinical outcome for gastric cancer patients treated with bolus 5-fluorouracil. Oncol Rep 2004;11:9-15.
51. Suda Y, Kuwashima Y, Tanaka Y, Uchida K, Sakamoto H, Hashiguchi Y, Sekine T: Expression of thymidylate synthase and thymidine phosphorylase in recurrence and survival rates of advanced gastric cancer. Gastric Cancer 1999;2:165-172.
52. van Triest B, Pinedo HM, Blaauwgeers JLG, van Diest PJ, Shoenmakers PS, Voorn DA, Smid K, Hoekman K, Hoitsma HFW, Peters GJ: Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res 2000;6:1063-1072.
53. Shirota S, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV, Lenz HJ: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001;19:4298-4304.
54. Iqbal S, Lenz HJ: Determinants of prognosis and response to therapy in colorectal cancer. Curr Oncol Rep 2001;3:102-108.